ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcutis Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$31.89+3.07 (+10.65%)
Close on Oct 19, 2026
- Market cap
- $4.33B
- P/E (TTM)
- 145.0
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
131M of 126M shares
Institutional holders
272
42 new, 36 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 77 sales
Net sold $16.20M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 9,534,837 | 9.99% | 13G (passive) amendment | Dec 31, 2023 |
| Patrick J. Heron | 8,943,712 | 7.50% | 13D (active) amendment | Aug 18, 2025 |
| David Rosen | 8,271,577 | 6.75% | 13G (passive) amendment | Dec 31, 2025 |
| Polar Capital LLP | 6,606,945 | 5.28% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 17,751,435 | 14.10% | 13G (passive) amendment | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ARQT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 12,437,000 | 9.89% | $326.10M | +110,000 | 5.96% |
| BlackRock, Inc. | 10,545,466 | 8.39% | $276.50M | +1,345,055 | 0.00% |
| Frazier Life Sciences Management, L.P. | 9,874,511 | 7.86% | $258.91M | – | 5.64% |
| Rubric Capital Management LP | 8,271,577 | 6.58% | $216.88M | – | 1.99% |
| Polar Capital Holdings Plc | 6,606,945 | 5.26% | $173.23M | +940,005 | 0.41% |
| State Street Corp | 5,822,840 | 4.63% | $152.67M | −473,357 | 0.00% |
| Vanguard Capital Management LLC | 4,988,756 | 3.97% | $130.81M | +117,220 | 0.00% |
| Morgan Stanley | 4,451,014 | 3.54% | $116.71M | +232,083 | 0.01% |
| Jennison Associates LLC | 4,219,058 | 3.36% | $110.62M | −761,712 | 0.07% |
| D. E. Shaw & Co., Inc. | 3,949,609 | 3.14% | $103.56M | +1,453,387 | 0.05% |
| UBS Group AG | 3,333,015 | 2.65% | $87.39M | +3,791 | 0.01% |
| Bank Of America Corp /De/ | 2,987,431 | 2.38% | $78.33M | +766,142 | 0.01% |
| Geode Capital Management, LLC | 2,982,446 | 2.37% | $78.21M | −62,860 | 0.00% |
| Vanguard Portfolio Management LLC | 2,429,005 | 1.93% | $63.69M | +474,320 | 0.00% |
| Orbimed Advisors LLC | 2,042,000 | 1.62% | $53.54M | New | 0.99% |
| Franklin Resources Inc | 1,930,982 | 1.54% | $50.63M | −366,961 | 0.01% |
| American Century Companies Inc | 1,925,031 | 1.53% | $50.47M | +461,803 | 0.02% |
| Goldman Sachs Group Inc | 1,668,367 | 1.33% | $43.74M | +65,354 | 0.00% |
| Jupiter Topco LLC | 1,410,435 | 1.12% | $36.99M | New | 0.02% |
| Oberweis Asset Management Inc/ | 1,372,941 | 1.09% | $36.00M | +7,000 | 0.74% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 272 | 131M | 100.0% | 42 / 95 | 100 / 36 | 18M | 18M |
| Q1 2026 | 270 | 133M | 100.0% | 41 / 104 | 88 / 48 | 21M | 10M |
| Q4 2025 | 283 | 129M | 100.0% | 74 / 102 | 78 / 25 | 20M | 17M |
| Q3 2025 | 239 | 126M | 100.0% | 34 / 87 | 84 / 21 | 9M | 10M |
| Q2 2025 | 230 | 127M | 100.0% | 35 / 89 | 67 / 45 | 13M | 11M |
| Q1 2025 | 241 | 126M | 100.0% | 64 / 67 | 80 / 29 | 8M | 11M |
| Q4 2024 | 208 | 129M | 100.0% | 49 / 60 | 65 / 28 | 15M | 16M |
| Q3 2024 | 188 | 130M | 100.0% | 34 / 72 | 48 / 31 | 20M | 10M |
| Q2 2024 | 186 | 128M | 100.0% | 47 / 59 | 55 / 29 | 21M | 27M |
| Q1 2024 | 168 | 134M | 100.0% | 59 / 52 | 40 / 23 | 43M | 16M |
| Q4 2023 | 133 | 107M | 85.5% | 40 / 51 | 24 / 40 | 60M | 20M |
| Q3 2023 | 134 | 67M | 53.4% | 18 / 53 | 38 / 18 | 3M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ARQT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,564,957 | 2.84% | $93.47M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,937,192 | 2.34% | $77.01M | 0.09% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,914,129 | 2.32% | $76.41M | 0.71% | Jun 30, 2026 |
| Small Cap Growth Fund | 1,466,411 | 1.17% | $39.39M | 0.71% | Jul 31, 2026 |
| PGIM Jennison Small Company Fund | 1,386,237 | 1.10% | $36.35M | 1.04% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,308,312 | 1.04% | $34.30M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,250,551 | 0.99% | $33.59M | 0.10% | Jul 31, 2026 |
| Oberweis Small-Cap Opportunities Fund | 1,211,800 | 0.96% | $31.77M | 1.12% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,056,318 | 0.84% | $27.70M | 0.18% | Jun 30, 2026 |
| Baron Discovery Fund | 867,400 | 0.69% | $22.74M | 1.24% | Jun 30, 2026 |
| iShares Biotechnology ETF | 782,595 | 0.62% | $20.52M | 0.23% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 576,471 | 0.46% | $12.37M | 0.03% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 565,357 | 0.45% | $12.13M | 0.07% | May 31, 2026 |
| Vanguard Explorer Fund | 561,183 | 0.45% | $15.07M | 0.07% | Jul 31, 2026 |
| Schwab U.S. Small-Cap ETF | 534,058 | 0.42% | $11.46M | 0.05% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Todd Watanabe | See Remarks, Director | 899,517 | 0.72% | Aug 5, 2026 |
| Masaru Matsuda | See Remarks | 112,508 | 0.09% | Sep 18, 2026 |
| Patrick Burnett | See Remarks | 117,592 | 0.09% | Aug 21, 2026 |
| Latha Vairavan | SVP Chief Financial Officer | 85,978 | 0.07% | May 13, 2026 |
| Larry Todd Edwards | See Remarks | 175,178 | 0.14% | Mar 3, 2026 |
| David Joseph Topper | Chief Financial Officer | 182,774 | 0.15% | Apr 3, 2025 |
| Howard G. Welgus | Director | 63,307 | 0.05% | Sep 17, 2026 |
| Terrie Curran | Director | 23,526 | 0.02% | Aug 28, 2026 |
| Christopher Peetz | Director | 191,815 | 0.15% | Jul 17, 2026 |
| Sue-Jean Lin | Director | 27,567 | 0.02% | Jun 17, 2026 |
| Patrick J. Heron | Director | 59,661 | 0.05% | Jun 12, 2026 |
| Neha Krishnamohan | Director | 27,901 | 0.02% | Jun 9, 2026 |
| Halley E. Gilbert | Director | 27,901 | 0.02% | Jun 9, 2026 |
| Keith R. Leonard | Director | 29,651 | 0.02% | Jun 9, 2026 |
| Amit Munshi | Director | 9,799 | 0.01% | Jun 9, 2026 |
| Bhaskar Chaudhuri | Director | 917,807 | 0.73% | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Masaru Matsuda See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −3,674 | $25.00 | $91.85K | 112,508 |
| Howard G. Welgus Director | Sep 15, 2026 | Option exercise | +1,019 | $7.51 | $7.65K | 38,316 |
| Howard G. Welgus Director | Sep 15, 2026 | Option exercise | +2,255 | $8.63 | $19.46K | 40,571 |
| Howard G. Welgus Director | Sep 15, 2026 | Sale(10b5-1 plan) | −4,730 | $24.18 | $114.37K | 35,841 |
| Howard G. Welgus Director | Sep 15, 2026 | Option exercise | +822 | $6.52 | $5.36K | 37,297 |
| Masaru Matsuda See Remarks | Sep 8, 2026 | Sale(10b5-1 plan) | −9,989 | $25.03 | $250.02K | 116,182 |
| Terrie Curran Director | Aug 27, 2026 | Sale | −27,052 | $25.03 | $677.11K | 23,526 |
| Terrie Curran Director | Aug 27, 2026 | Option exercise | +11,148 | $7.51 | $83.72K | 34,674 |
| Terrie Curran Director | Aug 27, 2026 | Sale | −11,148 | $25.03 | $279.03K | 23,526 |
| Terrie Curran Director | Aug 27, 2026 | Option exercise | +27,052 | $8.63 | $233.46K | 50,578 |
| Terrie Curran Director | Aug 20, 2026 | Sale | −1,072 | $26.04 | $27.91K | 23,526 |
| Terrie Curran Director | Aug 20, 2026 | Option exercise | +1,072 | $7.51 | $8.05K | 24,598 |
| Patrick Burnett See Remarks | Aug 19, 2026 | Sale | −1,697 | $27.00 | $45.82K | 117,592 |
| Howard G. Welgus Director | Aug 17, 2026 | Sale(10b5-1 plan) | −4,730 | $26.18 | $123.83K | 36,475 |
| Howard G. Welgus Director | Aug 17, 2026 | Option exercise | +822 | $6.52 | $5.36K | 37,931 |
| Howard G. Welgus Director | Aug 17, 2026 | Option exercise | +1,019 | $7.51 | $7.65K | 38,950 |
| Howard G. Welgus Director | Aug 17, 2026 | Option exercise | +2,255 | $8.63 | $19.46K | 41,205 |
| Patrick Burnett See Remarks | Aug 12, 2026 | Option exercise | +6,700 | $3.64 | $24.39K | 125,989 |
| Patrick Burnett See Remarks | Aug 12, 2026 | Sale | −6,700 | $26.08 | $174.74K | 119,289 |
| Patrick Burnett See Remarks | Aug 11, 2026 | Option exercise | +8,300 | $3.64 | $30.21K | 127,589 |
| Patrick Burnett See Remarks | Aug 11, 2026 | Sale | −8,300 | $26.52 | $220.12K | 119,289 |
| Patrick Burnett See Remarks | Aug 3, 2026 | Sale(10b5-1 plan) | −955 | $26.12 | $24.94K | 119,289 |
| Masaru Matsuda See Remarks | Aug 3, 2026 | Sale(10b5-1 plan) | −1,230 | $26.12 | $32.13K | 126,171 |
| Todd Watanabe See Remarks, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −4,375 | $26.12 | $114.28K | 717,203 |
| Howard G. Welgus Director | Jul 15, 2026 | Option exercise | +822 | $6.52 | $5.36K | 38,565 |
| Howard G. Welgus Director | Jul 15, 2026 | Option exercise | +1,019 | $7.51 | $7.65K | 39,584 |
| Howard G. Welgus Director | Jul 15, 2026 | Sale(10b5-1 plan) | −4,730 | $26.91 | $127.28K | 37,109 |
| Howard G. Welgus Director | Jul 15, 2026 | Option exercise | +2,255 | $8.63 | $19.46K | 41,839 |
| Christopher Peetz Director | Jul 15, 2026 | Award | +4,315 | – | – | 4,315 |
| Howard G. Welgus Director | Jun 17, 2026 | Sale(10b5-1 plan) | −635 | $25.67 | $16.30K | 37,743 |
| Sue-Jean Lin Director | Jun 15, 2026 | Sale(10b5-1 plan) | −4,946 | $24.38 | $120.58K | 27,567 |
| Howard G. Welgus Director | Jun 15, 2026 | Sale(10b5-1 plan) | −4,096 | $24.41 | $99.98K | 38,378 |
| Howard G. Welgus Director | Jun 15, 2026 | Option exercise | +822 | $6.52 | $5.36K | 39,200 |
| Howard G. Welgus Director | Jun 15, 2026 | Option exercise | +1,019 | $7.51 | $7.65K | 40,219 |
| Howard G. Welgus Director | Jun 15, 2026 | Option exercise | +2,255 | $8.63 | $19.46K | 42,474 |
| Terrie Curran Director | Jun 5, 2026 | Award | +5,778 | – | – | 23,526 |
| Patrick J. Heron Director | Jun 5, 2026 | Award | +5,778 | – | – | 32,213 |
| Howard G. Welgus Director | Jun 5, 2026 | Award | +5,778 | – | – | 38,378 |
| Amit Munshi Director | Jun 5, 2026 | Award | +5,778 | – | – | 9,799 |
| Keith R. Leonard Director | Jun 5, 2026 | Award | +5,778 | – | – | 27,901 |
| Halley E. Gilbert Director | Jun 5, 2026 | Award | +5,778 | – | – | 27,901 |
| Sue-Jean Lin Director | Jun 5, 2026 | Award | +5,778 | – | – | 32,513 |
| Neha Krishnamohan Director | Jun 5, 2026 | Award | +5,778 | – | – | 27,901 |
| Latha Vairavan SVP Chief Financial Officer | May 11, 2026 | Sale(10b5-1 plan) | −435 | $21.05 | $9.16K | 85,978 |
| Patrick Burnett See Remarks | May 11, 2026 | Sale(10b5-1 plan) | −222 | $21.05 | $4.67K | 120,244 |
| Patrick Burnett See Remarks | May 4, 2026 | Sale(10b5-1 plan) | −684 | $23.61 | $16.15K | 120,466 |
| Latha Vairavan SVP Chief Financial Officer | May 4, 2026 | Sale(10b5-1 plan) | −1,341 | $23.61 | $31.66K | 86,413 |
| Masaru Matsuda See Remarks | May 4, 2026 | Sale(10b5-1 plan) | −884 | $23.61 | $20.87K | 126,689 |
| Masaru Matsuda See Remarks | May 4, 2026 | Sale(10b5-1 plan) | −7,372 | $23.27 | $171.55K | 127,573 |
| Todd Watanabe See Remarks, Director | May 4, 2026 | Sale(10b5-1 plan) | −3,172 | $23.61 | $74.89K | 720,755 |
| Howard G. Welgus Director | May 1, 2026 | Sale(10b5-1 plan) | −7,144 | $22.99 | $164.24K | 32,600 |
| Howard G. Welgus Director | Apr 1, 2026 | Sale(10b5-1 plan) | −10,000 | $23.88 | $238.80K | 39,744 |
| Keith R. Leonard Director | Mar 2, 2026 | Option exercise | +27,052 | $8.63 | $233.46K | 49,175 |
| Keith R. Leonard Director | Mar 2, 2026 | Option exercise | +12,220 | $7.51 | $91.77K | 61,395 |
| Keith R. Leonard Director | Mar 2, 2026 | Sale(10b5-1 plan) | −39,272 | $25.39 | $997.12K | 22,123 |
| Howard G. Welgus Director | Mar 2, 2026 | Sale(10b5-1 plan) | −10,000 | $25.65 | $256.50K | 49,744 |
| Latha Vairavan SVP Chief Financial Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −2,772 | $25.16 | $69.74K | 87,835 |
| Latha Vairavan SVP Chief Financial Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −81 | $25.91 | $2.10K | 87,754 |
| Larry Todd Edwards See Remarks | Mar 2, 2026 | Sale(10b5-1 plan) | −103 | $25.91 | $2.67K | 175,178 |
| Larry Todd Edwards See Remarks | Mar 2, 2026 | Sale(10b5-1 plan) | −3,584 | $25.16 | $90.17K | 175,281 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Welgus Howard Director | Oct 15, 2026 | 4,728 | $127.33K | Oct 15, 2026 | Restricted Stock Vesting |
| Todd Edwards Larry Former Officer | Sep 16, 2026 | 341,980 | $8.55M | Sep 16, 2026 | Stock Option Exercise |
| Welgus Howard Director | Sep 15, 2026 | 4,730 | $114.37K | Sep 15, 2026 | Restricted Stock Vesting |
| Matsuda Masaru Officer | Sep 8, 2026 | 13,663 | $341.93K | Sep 8, 2026 | Restricted Stock Vesting |
| Curran Terrie Director | Aug 27, 2026 | 38,200 | $956.12K | Aug 27, 2026 | Stock Option Exercise |
| Curran Terrie Director | Aug 20, 2026 | 1,072 | $27.91K | Aug 20, 2026 | Stock Option Exercise |
| Burnett Patrick Officer | Aug 19, 2026 | 1,697 | $45.82K | Aug 19, 2026 | Restricted Stock Vest |
| Welgus Howard Director | Aug 17, 2026 | 4,730 | $123.83K | Aug 17, 2026 | Restricted Stock Vesting |
| Burnett Patrick Officer | Aug 11, 2026 | 15,000 | $397.82K | Aug 11, 2026 | Stock Option Exercise |
| Masaru Matsuda Officer | Aug 3, 2026 | 1,230 | $32.12K | Aug 3, 2026 | Restricted Stock Vesting |
| Frank Watanabe Todd Officer | Aug 3, 2026 | 4,375 | $114.26K | Aug 3, 2026 | Restricted Stock Vesting |
| Burnett Patrick Officer | Aug 3, 2026 | 955 | $24.94K | Aug 3, 2026 | Restricted Stock Vesting |
| Welgus Howard Director | Jul 15, 2026 | 4,730 | $127.28K | Jul 15, 2026 | Restricted Stock Vesting |
| Welgus Howard Director | Jun 17, 2026 | 635 | $16.30K | Jun 17, 2026 | Restricted Stock Vesting |
| Lin Sue-Jean Officer | Jun 15, 2026 | 4,946 | $120.59K | Jun 15, 2026 | Restricted Stock Vesting |